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Context—Sickle cell anemia (SCA) is a chronic illness causing progressive deterioration in
quality of life. Brain dysfunction may be the most important and least studied problem affecting
individuals with this disease.
Objective—To measure neurocognitive dysfunction in neurologically asymptomatic adults with
SCA vs healthy control individuals.
Design, Setting, and Participants—Cross-sectional study comparing neuropsychological
function and neuroimaging findings in neurologically asymptomatic adults with SCA and controls
from 12 SCA centers, conducted between December 2004 and May 2008. Participants were
patients with SCA (hemoglobin [Hb] SS and hemoglobin level ≤10 mg/dL) aged 19 to 55 years
and of African descent (n=149) or community controls (Hb AA and normal hemoglobin level)
(n=47). Participants were stratified on age, sex, and education.
Main Outcome Measures—The primary outcome measure was nonverbal function assessed by
the Wechsler Adult Intelligence Scale, third edition (WAIS-III) Performance IQ Index. Secondary
exploratory outcomes included performance on neurocognitive tests of executive function,
memory, attention, and language and magnetic resonance imaging measurement of total
intracranial and hippocampal volume, cortical gray and white matter, and lacunae.
Results—The mean WAIS-III Performance IQ score of patients with SCA was significantly
lower than that of controls (adjusted mean, 86.69 for patients with SCA vs 95.19 for controls
[mean difference, −5.50; 95% confidence interval {CI}, −9.55 to −1.44]; P =.008), with 33%
performing more than 1 SD (<85) below the population mean. Among secondary measures,
differences were observed in adjusted mean values for global cognitive function (full-scale IQ)
(90.47 for patients with SCA vs 95.66 for controls [mean difference, −5.19; 95% CI, −9.24 to
−1.13]; P =.01), working memory (90.75 vs 95.25 [mean difference, −4.50; 95% CI, −8.55 to
−0.45]; P =.03), processing speed (86.50 vs 97.95 [mean difference, −11.46; 95% CI, −15.51 to
−7.40]; P <.001), and measures of executive function. Anemia was associated with poorer
neurocognitive function in older patients. No differences in total gray matter or hippocampal
volume were observed. Lacunae were more frequent in patients with SCA but not independently
related to neurocognitive function.
Conclusion—Compared with healthy controls, adults with SCA had poorer cognitive
performance, which was associated with anemia and age.
Sickle cell anemia (SCA) WAS once associated with high pediatric mortality. While the
average life span for patients with SCA now exceeds 50 years,1,2 SCA has become a
chronic illness associated with progressive deterioration in quality of life.2,3 Neurocognitive
dysfunction may be the most important and least studied problem affecting this aging
population.4-8
The Cooperative Study of Sickle Cell Disease found that 24% of individuals with SCA
experienced a clinical stroke by age 45 years.4 Prospective pediatric imaging and
neurocognitive studies have identified the serious problem of unrecognized brain injury in
children with SCA.6,9,10 Global neurocognitive impairment was observed in patients with
overt strokes, but neurologically intact children also had impaired neurocognitive function
that increased with age. Declining IQ scores, learning difficulties, and impairment of
executive function were common in children with normal findings on imaging studies.9,11-16
To our knowledge, controlled studies of neurocognitive function in adult patients have not
been reported, and routine screening after childhood is not performed.
Several risk factors for ischemic brain dysfunction in SCA increase the likelihood of
neurocognitive impairment with age, including hypoxia and chronic anemia, and these have
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been associated with disturbances in cerebral oxygenation and perfusion4-8,17 in the general
population. If neurocognitive dysfunction is found to be common in adult patients with
SCA, it may contribute to deterioration of their quality of life.3
We hypothesized that neurologically asymptomatic adult patients with SCA and chronic
anemia (hemoglobin level ≤10 g/dL) would score lower on the Performance IQ (PIQ) Index
of the Wechsler Adult Intelligence Scale, third edition (WAIS-III) compared with
community controls. This measure of nonverbal function was chosen as the primary
outcome because of the strong association between nonverbal abilities and central nervous
system dysfunction in children with SCA. Secondary exploratory hypotheses included (1)
neurologically intact adults with SCA would have lower scores on other measures of
neurocognitive function; (2) impairment on these measures of neurocognitive function
would be associated with abnormal magnetic resonance imaging (MRI) results; and (3)
volumetric MRI would detect brain dysfunction in patients with abnormal neurocognitive
test results but normal qualitative MRI results.
METHODS
Participants
This cross-sectional study was designed to compare neuropsychological function in
neurologically asymptomatic adult patients with hemoglobin (Hb) SS and Sβ0thalassemia
(Sβ0) with healthy control individuals from their communities. Patients aged 19 to 55 years
with hemoglobin electrophoresis confirmation of their diagnosis and hemoglobin levels of
10 g/dL or less were eligible.
Patients routinely seen in the clinic setting were enrolled from 12 US medical centers
participating in the Comprehensive Sickle Cell Centers program between December 2004
and May 2008. Because approximately 95% of the patients with SCA cared for at these
centers are of African descent, to ensure sample homogeneity all of the individuals enrolled
in the study were African American (self-reported). Enrollment was stratified using age
(19-29, 30-39, 40-49, and 50-55 years), sex, and education (≤8 years, 9-11 years, high
school completion, >12 years). A 3:1 stratified enrollment ratio of patients to controls was
used so that estimates for patients would have a high degree of confidence while enrolling a
sufficient number of controls for 80% power in a patient-control comparison.
Patients with any history of neurologic injury, stroke, or abnormal neurologic examination
or imaging findings were excluded. Patients with serious cognitive impairment, depression,
or both were excluded by screening with the Mini-Mental State Examination18 and Profile
of Mood States.19 Patients with a chronic disorder (eg, diabetes, chronic lung disease,
hypertension, liver or renal disease), recent acute illness, or medication use that could affect
neurocognitive function were excluded. Patients with a history of recent transfusions and Hb
A level greater than 15% were not eligible. All patients completed neurocognitive testing
and neuroimaging at steady state.
Controls of African American descent with Hb AA on electrophoresis and a normal
hemoglobin level (>12 g/dL for women, >13.5 g/dL for men) were recruited from the same
communities with the same exclusionary criteria. Recruitment of controls was facilitated
through mailing of institutional review board–approved information flyers. Additionally,
controls were recruited from local churches, shopping centers, colleges, hospital staffs, and
community events.
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Written informed consent was provided by 214 patients and 72 controls. Fifty-four patients
and 20 controls did not meet eligibility requirements after screening. Of the 160 patients and
52 controls enrolled, 11 patients and 5 controls were discontinued prior to completing the
neuropsychological battery or MRI. A total of 149 patients and 47 controls completed
neuropsychological batteries, MRIs, or both, resulting in participation rates of 93% and
90%, respectively. The neurocognitive battery was completed by 146 patients and 47
controls, while 141 patients and 44 controls completed the MRIs. Eighty-two patients and 22
controls had MRIs of sufficient quality for complete volumetric analysis. Reasons for
volumetric MRI failure were related to coordinating a multicenter MRI study and not to
participant-related reasons.
Participating Centers and Data Collection
This study was conducted using Good Clinical Practice guidelines.20 Institutional review
boards at each site approved the study. Each institution had a principal investigator,
neuropsychologist, radiologist, and coordinator assigned to the study.
Neuropsychological Protocol
Participating neuropsychologists were trained to administer and score the neurocognitive
protocol. All data were reviewed, rescored, and validated by the coordinating center
neuropsychologist. The assessment protocol measured global cognitive function, executive
function, academic achievement, memory, attention, motor skills, and processing speed.
Tests, functions, and score characteristics for neurocognitive measures are detailed in Table
1. The scores for the analyses were adjusted for age at the time of testing.
Evaluations were completed across 2 sessions lasting approximately 6 to 7 hours.
Participants were debriefed at study conclusion by the neuropsychologist and local
investigators. This included outlining cognitive strengths and weaknesses.
Recommendations and consultations were provided to address any concerns related to
mental health, memory, motor impairment, problem solving, planning, and organization.
MRI Evaluation
The University of California, San Francisco, Neuroimaging Center was the MRI reading
center. A standardized protocol, software, and 1.5-T newer-generation scanners with
volumetric T1-weighted MRI acquisition capability were used.
Phantom scans were provided by each site for assessment of qualification and reliability.
Central readings were performed by 2 qualified independent neuroradiologists masked to the
participant’s medical history. Descriptive analysis was standardized. Lacunae were defined
as regions of at least 5 mm in diameter that were hyperintense on the T2-weighted images as
well as the proton-density weighted images, with corresponding hypointensity on T1-
weighted images.
Volumetric measurements included total intracranial volume, hippocampal volume, cortical
gray matter, white matter, and cortical and subcortical lacunae. Intracranial volume was
determined by creating a binary mask of the T2-weighted image. Hippocampal volumes
were obtained using Surgical Navigation Technologies, a brain-mapping method based on a
high-dimensional fluid transformation algorithm.21 The Expectation Maximizing
Segmentation algorithm22 was used to segment all MRIs into gray matter, white matter, and
cerebrospinal fluid. Output was confirmed with a segmentation review combined with the
corresponding lobe parcellation results. An atlas-based method was used to identify the
lobes and subcortical nuclei, 23 with the MRI of a healthy 36-year-old man as the reference.
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An entropy-driven B-spline free-form deformation algorithm24 was used to register
individual scans to the reference atlas. All automated marked MRIs were visually inspected
to ensure accuracy. The lobar and subcortical markings were then combined with the
Expectation Maximizing Segmentation tissue masks to generate measurements of gray
matter, white matter, and cerebrospinal fluid by lobe.
Statistical Analysis
Based on a priori sample-size calculations, a sample of 120 patients and 36 controls would
have 80% power, with a 2-sided α of .05, to detect an 8-point difference (>0.5 SD and
clinically significant) on the WAIS-III PIQ Index. The primary hypothesis (WAIS-III PIQ
score) was tested at the .05 α level; no adjustments for multiple comparisons on the
secondary analyses were made, because these P values were considered exploratory.
Demographic and baseline measures were descriptively compared for imbalance using the
Fisher exact test for categorical variables and Wilcoxon 2-sample nonparametric test for
continuous variables. No missing data were imputed, but the effects of possible biases
attributable to missing data were studied using sensitivity analyses.
To compare patients and controls, mixed linear models were fit to the data for each test.
Each mixed model had age, sex, education, group, subtest, and the group × subtest
interaction as fixed effects and random intercepts at the participant level to account for the
within-participant correlations between an individual’s set of subtests within each test.
Using the mixed models, 2-sided significance tests were completed and 2-sided 95%
confidence intervals (CIs) were constructed for differences in each subtest. Categories of the
WAIS-III measures were designated by the number of standard deviations away from the
mean and the percentage of patients and controls in each category reported compared with
expected norms. The WAIS-III norms are based on a representative sample of the US adult
population and include the range of ethnic/racial and socioeconomic categories that exists in
the general population.
General linear models of volumetric MRI measures were fit, adjusting for total intracranial
volume, age, and group. A group × age interaction was used to estimate age-dependent
patient minus control differences. χ2 Tests were used to assess the statistical significance of
patient-control differences in clinical MRI event prevalence.
The differences between the groups were statistically significant for WAIS-III PIQ score
and the presence of lacunae. An additional general linear model was fit to the subset of data
that included patients with lacunae, patients without lacunae, and controls without lacunae.
To explore possible confounding of age on these results, age was added to the model and the
2 sets of model results were compared. To explore the relationship between PIQ score and
hemoglobin level among the patients, 4 strata of age (<25, 25 to 30, 30 to 40, and ≥40 years)
were created based approximately on quartiles of the data. Also, 4 strata of hemoglobin level
(<7.6, 7.6 to <8.3, 8.3 to <9.0, and ≥9.0 g/dL) were created. Within each stratum
combination, the sample size, mean PIQ score, and standard deviation were tabulated.
Statistical analyses were generated using SAS version 9.1 (SAS Institute Inc, Cary, North
Carolina).
RESULTS
Analyses were performed to identify differences between participants with and without
volumetric MRI results, as well as those with and without results for neuropsychological
batteries or clinical MRIs. No significant differences were observed in the demographic or
disease variables, WAIS-III measures, or MRI measures of atrophy, lacunae, or white matter
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lesion incidence. Even though a large proportion of the MRIs were volumetric MRI failures,
the failures did not appear to impose a bias on the volumetric MRI comparisons between
patients and controls.
Mean patient age was 31.6 (SD, 8.95) years vs 33.1 (SD, 10.06) years for controls (P =.45);
63% of patients were women, and 95% had Hb SS. Compared with controls, patients had
lower mean hemoglobin values (8.3 [SD, 0.98] g/dL vs 13.8 [SD, 1.13] g/dL) and higher
values than controls for Hb F, platelets, white blood cells, and lactate dehydrogenase (Table
2).
Neurocognitive Findings
Comparison of the primary neurocognitive outcome (WAIS-III PIQ score) between adult
patients with SCA and controls is summarized in the Figure. After adjusting for age, sex,
and education level, the patients had statistically significant lower mean scores than controls
(adjusted mean, 89.69 for patients vs 95.19 for controls [mean difference, −5.50; 95% CI,
−9.55 to −1.44]; P = .008). The WAIS-III PIQ score was more than 1 SD below the
normative mean for 33% of patients and 15% of controls, compared with an expected 16%
from the national norms (Table 3).
Additional differences between patients and controls were noted on mean scores for
secondary measures of processing speed (adjusted mean, 86.50 for patients vs 97.95 for
controls [mean difference, −11.46; 95% CI, −15.51 to −7.40]; P <.001), working memory
(90.75 vs 95.25 [mean , −4.50]; 95% CI, −8.55 to −0.45]; P =.03), global cognitive function
(full-scale IQ) (90.47 vs 95.66 [mean difference, −5.19; 95% CI, −9.24 to −1.13]; P =.01),
and the majority of measures of executive function (Delis-Kaplan Executive Function
System), after adjusting for age, sex, and education (Figure).
Difficulties with selective attention in patients were illustrated by lower mean scores for
visual scanning and attention on the Tests of Everyday Attention (map search [2 minutes]
adjusted mean difference, −1.39; 95% CI, −2.50 to −0.28; P =.01) and telephone search
(adjusted mean difference, −2.23; 95% CI, −3.32 to −1.15; P <.001) (Figure). The
differences in means between patients and controls were not statistically significant for other
TEA subtests or scales. Differences between patients and controls were not statistically
significant for any subtests from the Wechsler Memory Scale, third edition (memory),
Wisconsin Card Sorting Test, computer version 4 (cognitive flexibility), or California
Verbal Learning Test, second edition (verbal learning, recall, and recognition) (Figure).
MRI Findings
A cortical infarct was detected in 1 patient and 1 control. Lacunae were seen in 13% of
patients and 2% of controls (difference, 11%; 95% CI, 4.1% to 18.4%; P =.05) and were
mainly in the frontal lobe, parietal lobe, and basal ganglia. Atrophy was seen in 23% of
patients and 16% of controls (difference, 7%; 95% CI, −5.4% to 20.4%; P =.40), and white
matter lesions occurred in 15% of patients and 7% of controls (difference, 8%; 95% CI,
−1.4% to 17.6%; P =.21).
The difference between patients and controls in mean total intracranial volume was
statistically significant (1152.6 mL vs 1218.5 mL [difference, −65.9 mL; 95% CI, −125.2 to
−6.5]; P =.03). This difference represents 5.7% of the mean total intracranial volume among
patients. Exploratory analysis revealed that total intracranial volume decreased by 2.6 mL
per year on average among patients while remaining constant among controls (95% CI, −4.8
to −0.5). No statistically significant difference in total cortical gray matter volume
(difference, −1.58 mL; 95% CI, −7.11 to 10.26; P =.72) or total hippocampal volume
(difference, −0.16 mL; 95% CI, −0.16 to 0.49; P =.33) was observed between patients and
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controls when controlling for total intracranial volume, age, and group. Globally, there was a
statistically significant reduction in total cortical gray matter volume as age increased (−1.02
mL/y; 95% CI, −1.37 to −0.67; P <.001); however, group differences in the reduction were
not statistically significant (−0.85 mL/y among controls and −1.07 mL/y among patients
[difference, 0.22 mL/y; 95% CI, −1.04 to 0.60]; P =.59). A reduction in total hippocampal
volume with age was statistically significant in patients but not controls (−0.015 mL/y; 95%
CI, −0.03 to −0.005; P =.04).
Correlates of WAIS-III PIQ Score
Performance IQ score was not correlated with sex, white blood cell count, platelet count, or
levels of Hb F, lactate dehydrogenase, or hemoglobin. Further investigation suggested an
age-dependent relationship between PIQ score and hemoglobin level. As hemoglobin level
decreased, the difference in mean PIQ score between patients younger than 25 years and
those 40 years or older tended to increase (eTable, available at http://www.jama.com). A
similar pattern was not observed for verbal IQ, full-scale IQ, Perceptual Organizational
Index, and Verbal Comprehension Index scores, although patients with hemoglobin levels
less than 7.6 g/dL consistently had large reductions in mean score after the fourth decade.
Neither the Working Memory Index nor the Processing Speed Index demonstrated a
relationship with hemoglobin levels.
Patients with lacunae had the lowest mean WAIS-III PIQ scores compared with patients
without lacunae or controls without lacunae. Mean PIQ scores in patients with lacunae were
85.1 compared with 91.1 for patients without lacunae (difference, 6.0; 95% CI, 0.1 to 12.0;
P =.05). After adjusting for age, however, this difference was not statistically significant.
Additional analyses showed that total intracranial volume and total cortical gray matter
volume were not significantly correlated with PIQ score, and the correlation with total
hippocampal volume of 0.21 (95% CI, −0.01 to 0.41) was also not statistically significant.
COMMENT
To our knowledge, this is the first comprehensive assessment of neurocognitive function in
neurologically intact adults with SCA. The major findings are that (1) adults with SCA
showed poorer performance on neurocognitive tests when compared with community
controls; (2) anemia is associated with the age-related decline in cognitive performance; and
(3) MRI findings do not explain the performance differences in the subset of patients with
neuroimaging studies, despite the presence of more lacunae infarcts in patients than in
controls.
Because silent infarction and impaired performance on neurocognitive tests was previously
demonstrated in neurologically intact pediatric patients, we studied a similar population of
adults with SCA who had no previous history of neurologic events or of abnormal findings
on imaging or neurologic examination. The study sample excluded patients with chronic
disease and complications of SCA resulting in end-organ failure that are known to be
associated with neurocognitive dysfunction. While the study sample is not representative of
the entire SCA population, it represents an important subgroup of neurologically intact
individuals without evidence of other organ dysfunction.
The study demonstrates important differences in neurocognitive performance on the WAIS-
III verbal IQ, PIQ, and full-scale IQ indexes, as well as on tests of memory, language,
learning, attention, retrieval, and overall executive functioning. Executive functioning
includes cognitive ability, volition, planning, and effective execution of plans.26,27 While
the mean scores of the patients with SCA are at the low end of the average range, 33% of
this group had PIQ scores in the below-average range, suggesting possible challenges in
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skills of daily life such as employment, financial management, medication adherence,
utilization of community resources, and social functioning.27,28 The majority of adult
patients with SCA have other sickle cell–related complications and risk factors4,29,30
associated with neurocognitive decline in the general population,29 such as chronic lung
disease, renal failure, stroke, intracranial hemorrhage, chronic liver disease, mental health
disorders, and systemic hypertension. Therefore, these results may underestimate the level
of cognitive difficulties experienced in the larger community of adults with SCA.
Hemoglobin level, age, and education were associated with lower neurocognitive
performance. We found no association between PIQ scores and lung injury, disease severity,
Hb F level, white blood cell count, platelet count, or lactate dehydrogenase level.
Anemia is a potentially important correlate for poorer neurocognitive performance in this
population, as indicated by the effect of anemia on age-related neurocognitive decline.
Previous studies have consistently found reduced hemoglobin levels to be a risk factor for
neurocognitive dysfunction in individuals with SCA as well as the general population.11-14
Hemoglobin is likely a surrogate marker for reduced oxygen delivery to the brain. Increased
cerebral blood flow is associated with lower cognitive function and is caused by anemia and
hypoxia.13,31 Patients with SCA appear to have a decreased cerebral vascular reserve and
may have a state of chronic cerebral ischemia resulting in neurocognitive dysfunction. This
is supported by studies that find lower cerebral oxygen saturation in patients with SCA than
in controls and that also indicate that performance associated with anemia and oxygen
desaturation may be reversible. 32-34 Both transfusion and administration of hydroxyurea
may improve cerebral blood flow, oxygenation, and neurocognitive function in patients with
SCA.15,32,35 In studies of healthy controls and other chronic diseases, anemia is predictive
of poorer neurocognitive performance, and increasing hemoglobin levels improves test
results. 33,34 These observations suggest that a possible cause of cognitive difficulties in
SCA is diffuse, possibly reversible, hypoxic dysfunction.
Compared with controls, patients with SCA had an increased number of lacunae, reduced
total intracranial volume, and reduced total hippocampal volume with age. Patients with
SCA both with and without lacunae had a significant reduction in PIQ scores compared with
controls without lacunae. When adjusted for age, however, the effect of lacunae on cognitive
function in SCA was no longer statistically significant. Other MRI measures did not
significantly correlate with PIQ scores. Anemia appears to be a more important correlate
with neurocognitive performance; however, a larger sample size is necessary to establish a
lack of relationship between MRI findings and neurocognitive function. Furthermore, other
studies in SCA have found that anemia is a stronger predictor of neurocognitive function
than silent MRI findings.12,14
The quantitative MRI results of this study demonstrate preliminary evidence that total
intracranial and hippocampal volumes decrease with age in patients with SCA but not
controls. The lack of correlation of total intracranial volume and hippocampal volume with
age in the control group may indicate that volume loss is accelerated in young patients with
SCA, but the narrow age range in patients and controls may limit the detection of some
volume loss in older controls. The neurocognitive impairment may be caused by cerebral
blood flow velocity and hypoxia.11,12,36 Because MRI does not accurately predict this
velocity, neurocognitive injury from anemia may be better predicted by functional flow
studies using transcranial Doppler ultrasonography.13,15,35,37
Study Limitations
By design, the patient group was limited to a healthy group of adult patients with SCA and
was not representative of the population at large. A more heterogeneous sample is needed
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for generalization to the population. Because this was a cross-sectional study, follow-up of
patients was not included. The age range of patients as well as controls was not distributed
widely enough to include older patients, thereby limiting some conclusions. Including a
control group with chronic anemia would strengthen the study. Because thalassemia and
other hemolytic anemias appear to pose a high risk of central nervous system injury
secondary to a vasculopathy or prothrombotic state, individuals with such disorders were not
recruited as controls.5 A homogeneous group of patients with nonhemolytic anemias would
be the ideal control but difficult to obtain.
Analysis of secondary outcome variables was exploratory in nature, and P values were not
corrected for multiple comparisons. Their interpretation should occur in the context of
patterns observed across a variety of neurocognitive test results. The reduced number of
individuals with a volumetric MRI result could have affected the estimate of the relationship
between MRI result findings and the neurocognitive measures. Also, the study did not
include functional or perfusion studies. This limits interpretation of the secondary analyses
and underscores the need for further investigation with longitudinal designs.
Summary and Recommendations
Adult patients with SCA who are neurologically asymptomatic are still at risk for
neurocognitive performance deficits, because their anemia may be inducing neurocognitive
impairment secondary to cerebral hypoxemia undetectable by standard neuroimaging
studies. Several practical steps can be taken. First, early identification of patients with
difficulties on specific measures of neurocognitive function may allow these patients to
enroll in and benefit from cognitive rehabilitation programs.27 Additionally, longitudinal
studies are necessary to understand and evaluate disease progression. These studies can be
linked to biological components to improve understanding of neurocognitive function in
SCA.
Overall, the results of this study suggest that neurocognitive performance is not adequately
explained by findings on standard neuroimaging studies and support the need for
intervention studies evaluating transfusion therapy, neuroprotective agents, hydroxyurea,
and oxygenation to determine whether such treatments will improve cognition.
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Figure. Neuropsychological Function: Age, Sex, and Education-Adjusted Mean Differences
Based on Model
Mean difference indicates mean patient minus control differences. Wechsler Adult
Intelligence Scale, third edition (WAIS-III) measures are index scores; Delis-Kaplan
Executive Function System (D-KEFS) and Tests of Everyday Attention (TEA) measures are
scaled scores. No attempt was made to normalize the mean differences or the 95%
confidence intervals (CIs) to a common scale, so no attempt should be made to compare
precision across tests without keeping in mind the natural scale of the raw data. Size of data
markers indicates the weight of each measure in the study. For patients, sample size for all
measures was n=146 except for D-KEFS number-letter switching and TEA map search (1
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min), map search (2 min), telephone search time, and lottery (n=145); TEA elevator
counting with distraction, visual elevator raw accuracy, and telephone search dual-task
decrement (n=144); and TEA visual elevator timing and elevator counting with reversal
(n=140). For controls, sample size for all measures was n=47 except for D-KEFS inhibition
switching and TEA elevator counting with reversal and telephone search dual-task
decrement (n=46); D-KEFS 20-question (20Q) initial abstraction, 20Q total questions, and
20Q total weighted achievement (n=45); and TEA map search (2 min) (n=44).
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Table 1
Neurocognitive Measures, Functional Area Assessed, and Score Characteristics
Measure Functional Area Assessed
Score Characteristics
Mean (SD) Range Clinical Significance
Primary outcome (WAIS-III
Performance IQ Index)
Index of nonverbal function; includes
5 subtests of visual and motor ability




  Verbal IQ Index Index of verbal function; includes 6
subtests of language, abstract
reasoning
100 (115)a 50-150b ≥70 to <85 indicate below
average; <70, impaired
  Full-scale IQ Index Global cognitive index composed of
performance IQ and verbal IQ; age
normed
100 (115)a 50-150b ≥70 to <85 indicate below
average; <70, impaired
  Processing Speed Index Index composite of 2 measures of
visual scanning speed with motor
response
100 (115)a 50-150b ≥70 to <85 indicate below
average; <70, impaired
  Working Memory Index Index composite of 3 measures of
auditory short-term memory
100 (115)a 50-150b ≥70 to <85 indicate below
average; <70, impaired
  Verbal Comprehension Index Index composite of 3 measures of
word knowledge, general information,
reasoning
100 (115)a 50-150b ≥70 to <85 indicate below
average; <70, impaired
  Perceptual Organization Index Index composite of 3 measures of
visual-motor perception and
organization of motor responses
100 (115)a 50-150b ≥70 to <85 indicate below
average; <70, impaired
 WMS-III Comprehensive set of 9 subtests
assessing short- and long-term
memory, auditory and visual memory
100 (115)a 50-150b ≥70 to <85 indicate below
average; <70, impaired
 WCST-CV4 Cognitive flexibility and ability to shift
“set”
50 (10)c 10-90b ≥37 to <42 indicate below
average; <36, impaired
 D-KEFS Integrated battery of 5 tests of planning
ability, verbal fluency, concentration,
deductive reasoning
10 (3)d 1-19 ≥3.0 to <7.0 indicate below
average; <3.0, impaired
 TEA 8 subtests of visual and auditory
attention
10 (3)d 1-19 ≥3.0 to <7.0 indicate below
average; <3.0, impaired
 CVLT-II Word learning over multiple trials;
both recall and recognition measures
0 (1) −4.0 to 4.0b ≤−1.5 indicates below
average
Abbreviations: CVLT-II, California Verbal Learning Test, second edition; D-KEFS, Delis-Kaplan Executive Function System; TEA, Tests of
Everyday Attention; WAIS-III, Wechsler Adult Intelligence Scale, third edition; WCST-CV4, Wisconsin Card Sorting Test, computer version 4;
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Table 2
Demographic and Baseline Measures Among Patients With Sickle Cell Anemia and Healthy Controls
Variable
No. (%)
P ValueaPatients (n = 160) Controls (n = 52)
Age, y
 <25 39 (27) 15 (32)
.85 25-30 44 (30) 8 (17)
 >30 63 (43) 24 (51)
Sex
 Men 54 (37) 24 (51)
.09
 Women 92 (63) 23 (49)
Diagnosisb
 Hb SS 139 (95) 0
NA
 Sβ0 7 (5) 0
 Hb AA 0 47 (100)
Education level, y
 ≤12 52 (36) 15 (32)
.62
 >12 93 (64) 32 (68)
Medical history
 Asthma 12 (8) 4 (9) .95
 Avascular necrosis 43 (29) 0 (0) <.001
 Headaches 31 (21) 5 (11) .11
Clinical values
 Hemoglobin (n = 146) (n = 47)
  Mean (SD), g/dL 8.2 (1.00) 13.8 (1.15) <.001
 Platelets (n = 145) (n = 46)
  Mean (SD), ×103/μL 395.9 (130.93) 262.2 (55.48) <.001
 WBC count (n = 146) (n = 47)
  Mean (SD), ×103/μL 10.3 (3.28) 6.2 (2.08) <.001
 Hemoglobin F (n = 131) (n = 34)
  Mean (SD), % of total Hb variants 10.5 (8.21) 0.6 (1.11) <.001
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Variable
No. (%)
P ValueaPatients (n = 160) Controls (n = 52)
 LDH (n = 92) (n = 37)
  Mean (SD), U/Lc 574.8 (412.99) 290.0 (151.55) <.001
 ALT (n = 146) (n = 47)
  Mean (SD), U/L 33.5 (33.84) 31.2 (17.77) .81
 AST (n = 145) (n = 47)
  Mean (SD), U/L 43.9 (20.85) 27.3 (10.95) <.001
Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase; Hb, hemoglobin; LDH, lactate dehydrogenase; NA, not
applicable; Sβ0, Sβ0 thalassemia; WBC, white blood cell.
SI conversion factors: To convert LDH, ALT, and AST values to μkat/L, multiply by 0.0167.
a
P values for categorical variables are based on Fisher exact or a Mantel-Haenszel test depending on sample size; P values for continuous variables




LDH values were normalized using Karavanen Location Scale Method.25 Reference laboratory ranges were chosen by using the ranges from the
laboratory with the most available data. Normalized value=(raw value–original laboratory lower limit of normal) × [(reference laboratory upper
limit of normal–reference laboratory lower limit of normal)/(original laboratory upper limit of normal–original laboratory lower limit of normal) +
reference laboratory lower limit of normal)].
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